• A pharmacogenomic test that identifies medications with significant gene-drug interactions to inform prescribing

  • Access impacts prescribing decisions: Patients whose providers did NOT have access to GeneSight ~two times more likely to receive antidepressant with significant GDIs1

  • GeneSight helped improve outcomes in multiple clinical studies: Level 1 evidence demonstrates 41% relative improvement in depression remission2


    Fact Sheets and Product Info:

    GeneSight Executive Summary Download PDF
    Real-world study finds psychiatric hospitalizations reduced after GeneSight® testing Learn More
    VA-sponsored Study Shows Utility of GeneSight Learn More


    1. Oslin DW, et al. JAMA. 2022;328(2):151-161.
    2. Albers R, et al. J Clin Psychopharmacol. 2025 Sep 3. doi: 10.1097/JCP.0000000000002061. Online ahead of print.

    Myriad Products